Recent Analyses from REDUCE-IT® Demonstrate Benefits of Vascepa®/Vazkepa® (Icosapent Ethyl) in Specific High-Risk Cardiovascular Disease Patient Groups
Saturday, April 06, 2024
Amarin Corporation plc (NASDAQ: AMRN) unveiled two data presentations at ACC.24, spotlighting the effects of VASCEPA®/VAZKEPA® (icosapent ethyl) in diminishing Major Adverse Cardiovascular Events (MACE) in patients with varying baseline Lipoprotein(a) [Lp(a)] levels. Furthermore, the presentations underscored the efficacy of VASCEPA/VAZKEPA in reducing the risk of cardiovascular (CV) events irrespective of baseline LDL-C level. Simultaneously, the findings from the REDUCE-IT analysis, examining the relationship between Lp(a) concentrations and CV risk, were published in the Journal of the American College of Cardiology (JACC) on the same day.
Nabil Abadir, MB. CH.B., Chief Medical Officer and Head of Global Medical Affairs at Amarin, emphasized the significance of these findings, stating, “These new findings provide additional important evidence about the clinical utility of VASCEPA/VAZKEPA and further demonstrate its value in reducing cardiovascular events in at-risk patients in key subgroups." Abadir also highlighted Amarin's commitment to advancing the medical community's understanding of VASCEPA/VAZKEPA's role and value in reducing cardiovascular events globally.
REDUCE-IT was a comprehensive cardiovascular outcomes study conducted over seven years, completed in 2018. It involved 8,179 patients across 11 countries, primarily in the United States, with LDL-C controlled to between 41-100 mg/dL by statin therapy and various cardiovascular risk factors, including persistent elevated triglycerides. The primary results of REDUCE-IT were previously published in The New England Journal of Medicine in November 2018, while the total events results were published in the Journal of the American College of Cardiology in March 2019.
Cardiovascular disease remains a leading cause of death globally, with millions of major adverse cardiovascular events occurring each year. Despite achieving target LDL-C levels, many patients still face significant cardiovascular risk, particularly those with elevated triglycerides. VASCEPA/VAZKEPA, containing the active ingredient icosapent ethyl, was approved by the U.S. FDA as the first prescription treatment for patients with persistent cardiovascular risk despite statin therapy. It has since been prescribed over twenty million times in the United States and is also approved in several other countries including Canada, China, and select European countries.
Overall, these findings underscore the importance of VASCEPA/VAZKEPA in reducing cardiovascular risk among at-risk patients, reinforcing its position as a valuable therapeutic option in cardiovascular disease management.
Source: amarincorp.com
